|
Name |
Eremofortin F
|
Molecular Formula | C26H38O6 | |
IUPAC Name* |
[(1R,2R,7S,8aS)-8a-(hydroxymethyl)-1-methyl-6-oxo-7-prop-1-en-2-yl-1,2,3,4,7,8-hexahydronaphthalen-2-yl] (4E,6E)-3,9-dihydroxy-2-methyldeca-4,6-dienoate
|
|
SMILES |
C[C@H]1[C@@H](CCC2=CC(=O)[C@@H](C[C@]12CO)C(=C)C)OC(=O)C(C)C(/C=C/C=C/CC(C)O)O
|
|
InChI |
InChI=1S/C26H38O6/c1-16(2)21-14-26(15-27)19(5)24(12-11-20(26)13-23(21)30)32-25(31)18(4)22(29)10-8-6-7-9-17(3)28/h6-8,10,13,17-19,21-22,24,27-29H,1,9,11-12,14-15H2,2-5H3/b7-6+,10-8+/t17?,18?,19-,21-,22?,24+,26-/m0/s1
|
|
InChIKey |
LSVIDWGNANJIBB-BFBLSFCDSA-N
|
|
Synonyms |
Eremofortin F
|
|
CAS | NA | |
PubChem CID | 139585727 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 446.6 | ALogp: | 3.2 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 32 | QED Weighted: | 0.28 |
Caco-2 Permeability: | -4.543 | MDCK Permeability: | 0.00001080 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.993 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.033 |
Blood-Brain-Barrier Penetration (BBB): | 0.538 | Plasma Protein Binding (PPB): | 77.75% |
Volume Distribution (VD): | 0.331 | Fu: | 13.99% |
CYP1A2-inhibitor: | 0.199 | CYP1A2-substrate: | 0.405 |
CYP2C19-inhibitor: | 0.104 | CYP2C19-substrate: | 0.879 |
CYP2C9-inhibitor: | 0.03 | CYP2C9-substrate: | 0.93 |
CYP2D6-inhibitor: | 0.327 | CYP2D6-substrate: | 0.667 |
CYP3A4-inhibitor: | 0.471 | CYP3A4-substrate: | 0.521 |
Clearance (CL): | 5.142 | Half-life (T1/2): | 0.491 |
hERG Blockers: | 0.03 | Human Hepatotoxicity (H-HT): | 0.319 |
Drug-inuced Liver Injury (DILI): | 0.122 | AMES Toxicity: | 0.208 |
Rat Oral Acute Toxicity: | 0.221 | Maximum Recommended Daily Dose: | 0.338 |
Skin Sensitization: | 0.17 | Carcinogencity: | 0.708 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.946 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004127 | 0.670 | D07DVK | 0.229 | ||||
ENC004660 | 0.657 | D0IT2G | 0.229 | ||||
ENC003895 | 0.625 | D0CW1P | 0.229 | ||||
ENC004128 | 0.513 | D02RQU | 0.228 | ||||
ENC002230 | 0.437 | D03SXE | 0.228 | ||||
ENC001526 | 0.365 | D0CZ1Q | 0.223 | ||||
ENC002137 | 0.346 | D0D1SG | 0.217 | ||||
ENC003292 | 0.336 | D0KR5B | 0.217 | ||||
ENC003294 | 0.324 | D0R7JT | 0.214 | ||||
ENC003293 | 0.321 | D0D2TN | 0.214 |